OCT New England Outsourcing in Clinical Trials Event

Biotech companies rely on CROs and other service providers to take care of the operational aspects of clinical trials and ultimately achieve market approval, so finding a trustworthy and efficient outsourcing partner is one of the most vital aspects of running a successful clinical trial.

The fourth annual Outsourcing in Clinical Trials New England conference will explore the latest and most important topics in the field of clinical outsourcing.

Industry experts speaking at OCT New England

The fourth annual OCT New England will bring together respected industry experts such as:

  • Robert D. Arbeit, MD – vice president, clinical development, Idera Pharmaceutics
  • Lori Barrentine – director clinical affairs, Pamlab
  • Christina Bodurow – senior director, external sourcing and business management, Eli Lilly
  • Mike Collins – VP global clinical operations, Alexion Pharmaceuticals
  • Meredith Frank-Molnia – clinical affairs manager, Anika Therapeutics
  • Brooke Mastrorio – director, clinical affairs, DePuy Spine
  • Daniel McCarthy – associate director clinical affairs, Radius Health
  • Lynn McGovern – director, clinical outsourcing, Millennium: The Takeda Oncology Company
  • Lynn Newbould – senior director, outsourcing and clinical contracts, Molecular Insight Pharmaceuticals
  • Hemant Patel – director clinical programs, Shire HGT
  • Joe Popowicz – director, clinical operations, Stryker
  • David Sherris – president and CEO, Paloma Pharmaceuticals
  • Susan Stewart, FRAPS, RAC – senior vice president regulatory, quality and compliance, Tokai Pharmaceuticals
  • Kathryn Stiede – director clinical operations, Avila Pharmaceuticals
  • Jennifer Sugarman – associate director clinical affairs, pSivida
  • Lisa Virzi – project manager, ARIAD Pharmaceuticals

Enhance your clinical trial outsourcing methodology

Whether you are a start-up or an established company looking to enhance your existing outsourcing methodology, OCT New England can help you ensure the smooth completion of clinical trial procedures.

The event will take place 25-26 September 2012 at the Renaissance Boston Waterfront Hotel in Boston, Massachusetts, US. Sign up today and stay tuned as we bring you a superb line-up of guest speakers, exciting content and a room full of the latest technologies to enhance your clinical capabilities. Arena International Events and the OCT New England advisory board members look forward to seeing you in September for this must-attend event.

Make an enquiry

Address
Arena International Events

John Carpenter House

John Carpenter Street

London

EC4Y 0AN

+44 207 936 6680 www.arena-international.com/octnewengland/

OCT New England Images

Products and Services

Video

White Papers

Related Projects



ADYNOVI for the Treatment of Adults and Adolescents with Haemophilia A



ADYNOVI® is an intravenous infusion indicated for the treatment of adults and adolescents with haemophilia A.

2nd May 2018

Hizentra for the Treatment of Patients with CIDP



Hizentra® (immune globulin subcutaneous 20% liquid) is a subcutaneous infusion indicated for the treatment of patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

5th April 2018

Biktarvy for the Treatment of HIV-I



Biktarvy® is a once-daily regimen indicated for the treatment of HIV-1 infection in adults that were previously not treated with anti-retroviral medicines.

19th February 2018

Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML)



Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML).

17th August 2017

Nuwiq, Anti-Haemophilic Factor (recombinant) for the Treatment of Haemophilia A



Nuwiq injection is the first recombinant anti-haemophilic factor (blood coagulation factor VIII) drug indicated for the treatment of patients with haemophilia A.

18th February 2016

Abilify (aripiprazole) Digital Medicine for Treatment of Schizophrenia



Abilify (aripiprazole), an orally administered dopamine partial agonist and a seratonin antagonist, was approved by US Food and Drug Administration (FDA) in November 2002 for the treatment of schizophrenia.

23rd November 2015

Press Release

Regional Offices

Arena International Events

John Carpenter House

John Carpenter Street

London

EC4Y 0AN

+44 207 936 6680 www.arena-international.com/octnewengland/
Close
Close
Close

Go Top